© GettyImages/Tanaonte

Guest Article

What does Brexit mean for biopharma companies?

By Mike Pears and Joel Beevers, Patent Attorneys at Potter Clarkson

January 1, 2021 marked the UK’s official separation from the EU and with that has come a raft of changes to how the nation will now do business with the rest of the world.

© GettyImages/vchal

Spotlight on Moderna funding declarations in patent filings

By Jane Byrne

Two US government agencies are investigating whether Moderna Therapeutics, the biotech company behind one of the leading Covid-19 vaccine candidates, was upfront about government funding in its filed or awarded patents, as required by federal law.

The US Patent and Trademark Office and case law have created confusion around IP

Sequenom case leaves pharma confused over patent law

By Fiona BARRY

US intellectual property (IP) rules and a string of recent court cases are reducing the types of inventions pharma companies can patent, and “calling into question entire portfolios,” says a specialist lawyer.